Product Theater Forging a New Path: Targeting Muscarinic Receptor Circuits in Schizophrenia Supported by Karuna
Registration Options
Activity Date: 04/18/2023
AAPP 2023 registration is closed.
Session Time and Location
The live session is complete.
Session Summary
Prior to the presentation, lunch will be served from 11:15-11:30 AM Eastern. The program should begin right at 11:30 AM Eastern; however, small delays are possible due to the meal. We thank you in advance for your patience.
Currently approved drugs for schizophrenia have proven useful; however, unmet medical needs still exist for this patient population. This program will shed light on an evolving class of investigational therapeutics that have shown great promise in schizophrenia by targeting muscarinic acetylcholine receptors in the brain.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
AAPP websites use cookies to personalize and enhance your experience.
By continuing to use the site, you agree to this collection.
Learn more.
System Update:
We are undergoing major upgrades right now, and we appreciate your patience.
If you need help, please use the support chat or email info@aapp.org.
Learn more.